Complications of intravenous immune globulin treatment in neurologic disease

Neurology

Volumn 47, Issue 3, 1996, Pages 674-677

  Brannagan, Thomas H ^a,b   Nagle, Keith J ^a   Lange, Dale J ^a   Rowland, Lewis P ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BONE MARROW TOXICITY; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIABETIC NEUROPATHY; DRUG INDUCED DISEASE; DYSPNEA; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; POLYMYOSITIS; PRIORITY JOURNAL; PROTEINURIA; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 0029819741     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.3.674     Document Type: Article

References (50)

1. National Institute of Health Consensus Conference: Intravenous immune globulin prevention and treatment of disease. JAMA 1990;264:3189-3193.
2. Thornton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994;35:260-268.
3. Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Arch Neurol 1993;50:135-136.
4. Dalakas MC, Ilia I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
5. van der Mèche FGA, Schmilz PIM, and the Dutch GuillainBarré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
6. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36: 838-845.
7. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-879.
8. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High dose IVIg in the management of MG. Arch Intern Med 1986;146: 1365-1368.
9. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of IVIg in relapsing-remitting multiple sclerosis. Arch Neurol 1992;49:1233-1236.
10. Chaudhrey V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-242.
11. Cook D, Dalakas MC, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990;40:212-214.
12. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gamma globulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients. Am J Med 1991;91:162-168.
13. Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with IVIg therapy. Neurology 1992;42: 1442-1443.
14. Amato AA, Cornman EW, Kissel JT. Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology 1994; 44:1652-1654.
15. Hart YM, Cortez M, Andermann F, et al. Medical treatment of Rasmussen's syndrome. Neurology 1994;44:1030-1036.
16. Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 1987;82:624-629.
17. Donatini B. Transient renal dysfunction in diabetic patients after IVIg therapy [letter]. J Intern Med 1992;232:376.
18. Phillips AO. Renal failure and intravenous immunoglobulin [letter]. Clin Nephrol 1992;37:217.
19. Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36:83-86.
20. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-139.
21. Ellie E, Combe C, Ferrer X. High dose intravenous immune globulin and acute renal failure [letter]. N Engl J Med 1992; 327:1032-1033.
22. Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin [letter]. Clin Nephrol 1992;37:216-217.
23. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611.
24. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649-1650.
25. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226.
26. Silbert PL, Knezevic \W, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-258.
27. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994;121:259-262.
28. Vera-Ramirez M, Charlet M, Parry GJ. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for CIDP. Neurology 1992;42:1636-1637.
29. Casteels-van Daele M, Wijndaele L, Brock P, Kruger M, Gillis P. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy. J Neurol Neurosurg Psychiatry 1992;55:980-981.
30. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin [letter]. N Engl J Med 1991; 326:270-271.
31. Bower LR, Brey RL, Rogers SJ, Stroncek DF, Jackson CE. Intravenous immunoglobulin-induced neutropenia [abstract]. Ann Neurol 1994;36:291.
32. Majer RV, Green PJ. Neutropenia caused by intravenous immunoglobulin [letter]. BMJ 1988;296:1262.
33. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Beekman EM. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992;120:926-928.
34. Barucha C, McMillan JC. Eczema after intravenous infusion of immunoglobulin [letter]. BMJ 1987;295:1141.
35. Chan-Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion [letter]. Lancet 1987;i:1436.
36. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-262.
37. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica (Suppl) 1993;78:35-40.
38. Lisak RP. Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sei 1996;135:85-88.
39. Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987;82:633-635.
40. Nicholls MD, Cummins JC, Davies VJ, Greenwood JK. Haemolysis induced by intravenously administered immunoglobulin. Med J Aust 1989;150:404-406.
41. Cooperative Group for the Study of Immunoglobulin in chronic lymphocytic leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 1988;319:902-907.
42. National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Eng J Med 1991;325:73-80.
43. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-292.
44. Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 1996;19: 388-391.
45. Olbricht CJ, Stark E, Helmchen U, Schulze M, Brunkhorst R, Koch KM. Glomerulonephritis associated with inflammatory demyelinating polyradiculoneuropathy: a case report and review of the literature. Nephron 1993;64:139-141.
46. Hopper AH, Wijdicks EFM, Truax BT. Guillain-Barré syndrome. Philadelphia: F.A. Davis, 1991.
47. Lederman HM, Roifman CM, Lavi S, Gelfand EW. Corticosteriods for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med 1986;81:443-446.
48. Koffman B, Dalakas MC. Effect of high-dose intravenous immunoglobulin (IVIg) on hematological and serum chemistry profiles in the treatment of patients with neuromuscular diseases [abstract]. Neurology 1995;45(suppl 4):A235.
49. Horowitz B, Prince AM, Horowitz MS, Watklevicz C. Viral safety of solvent-detergent treated blood products. In: Brown F, ed: Virological safety aspects of plasma derivatives. Dev Biol Stand. Basel: Karger, 1993;81:147-161.
50. Prince AM, Horowitz B. Hepatitis C and immune globulin - [letter]. N Engl J Med 1995;332:1236.